14th Biosimilars Congregation

Date: Thursday, December 12, 2019                                          Venue: Kohinoor Continental Hotel, Mumbai

According to Morgan Stanley, the global biosimilar market will be US$ 240 billion and Indian market will be US$ 35 billion by 2030. This highlights that Biosimilars offers a very big opportunity. The 14th Biosimilar Congregation 2019 will discuss present and future scenario of the biosimilar market in India, current landscape, challenges and policy updates for global biosimilars, the state of biotech funding in India, permits licensing and direct cost issues, challenges in the development of biosimilars and address regulatory challenges and guidelines for approvals of biosimilars. 

Harness our Expertise:  

  • 30+ Biologics and Biosimilar studies experience
  • 19 Innovative Biologics (mABs) across 200 +sites
  • 14 Biosimilars including 3 Phase 1-PK/PD across 100+ sites
  • 11 Marketing Authorizations for innovative Biologics and
  • 02 Marketing Authorizations for Biosimilars

To know more, schedule a meeting with Navitas Life Sciences Experts at Booth#1  

Koushik Ganguly
Vice President, Clinical Operations
Navitas Life Sciences

Schedule your Meeting
First Name
Last Name
Business Email
Phone Number
Area of Interest (check all that apply)
Other (please provide any additional areas for discussion)

© 2019 Navitas Life Sciences | Privacy Policy